Unraveling noncoding DNA variants and epimutations: a paradigm shift in hereditary cancer research
Future Oncology · 2024
DOI: 10.2217/fon-2023-0665 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Future Oncology, 2024. Verfasst von Maria Baz Ibrahim und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncogenetics & Tumor Biology, Paul Brousse Hospital, Villejuif, France. Hauptthemen laut MEDLINE: Genetic Predisposition to Disease, Neoplasms, Epigenesis, Genetic, Mutation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Exhaustive efforts have been dedicated to uncovering genomic aberrations linked to cancer susceptibility. Noncoding sequence variants and epigenetic alterations significantly influence gene regulation and could contribute to cancer development. However, exploring noncoding regions in hereditary cancer susceptibility demands cutting-edge methodologies for functionally characterizing genomic discoveries. Additionally, comprehending the impact on cancer development of variants in noncoding DNA and the epigenome necessitates integrating diverse data through bioinformatic analyses. As novel technologies and analytical methods continue to advance, this realm of research is rapidly gaining traction. Within this mini-review, we delve into future research domains concerning aberrations in noncoding DNA regions, such as pseudoexons, promoter variants and cis-epimutations. [Box: see text].
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncogenetics & Tumor Biology, Paul Brousse Hospital, Villejuif, France.
- Department of Surgery & Cancer, Ovarian Cancer Action Research Centre, Imperial College London, London, W12 8EE, UK.
- International Department of Medical Oncology, Gustave Roussy, 94805, Villejuif, France.
- Department of Biology & Pathology-Cancer Genetics Laboratory, Gustave Roussy, 94805, Villejuif, France.
ORCID-Profile: Tony Ibrahim
Zitieren
APA
Ibrahim, M. B., Flanagan, J., Ibrahim, T., & Rouleau, E. (2024). Unraveling noncoding DNA variants and epimutations: a paradigm shift in hereditary cancer research. Future Oncology. https://doi.org/10.2217/fon-2023-0665
Vancouver
Ibrahim MB, Flanagan J, Ibrahim T, Rouleau E. Unraveling noncoding DNA variants and epimutations: a paradigm shift in hereditary cancer research. Future Oncology. 2024. doi:10.2217/fon-2023-0665
BibTeX
@article{Ibrahim2024,
author = {Ibrahim, Maria Baz and Flanagan, James and Ibrahim, Tony and Rouleau, Etienne},
title = {Unraveling noncoding DNA variants and epimutations: a paradigm shift in hereditary cancer research},
journal = {Future Oncology},
year = {2024},
doi = {10.2217/fon-2023-0665}
}
EUVIMED